FDA approves belzutifan plus lenvatinib for advanced RCC with a clear cell component after PD-1 or PD-L1 inhibitor therapy.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma (RCC) with a clear cell component (ccRCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
The September 24, 2026 approval establishes the combination as an additional treatment option for patients whose disease has progressed on or after PD-1 or PD-L1 inhibitor therapy, including those whose disease progressed within six months of completing adjuvant PD-1 inhibitor therapy.
Phase 3 LITESPARK-011 Supports FDA Approval
The approval is supported by Phase 3 LITESPARK-011 (NCT04586231), an open-label, randomized, active-controlled trial involving 747 patients with advanced ccRCC. Participants received either belzutifan plus lenvatinib or cabozantinib. PFS, assessed by blinded independent central review using RECIST 1.1, and OS were major efficacy endpoints, while ORR was an additional outcome measure.
Median PFS was 14.6 months with belzutifan plus lenvatinib versus 10.6 months with cabozantinib, corresponding to a PFS hazard ratio of 0.74 (95% CI, 0.61–0.89; one-sided P=0.00095). ORR was 53% versus 40%, respectively, with a one-sided P value of 0.0002.
The final OS analysis was not statistically significant. Median OS was 33.7 months with the combination and 28.6 months with cabozantinib, with an OS hazard ratio of 0.85 (95% CI, 0.70–1.03).
Belzutifan Targets HIF-2α
Belzutifan is an oral inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor involved in cellular responses to low oxygen. The drug binds HIF-2α and prevents its interaction with HIF-1β, reducing transcription of HIF-2α target genes involved in tumor biology.
Lenvatinib is a multikinase inhibitor. The approved regimen therefore combines HIF-2α pathway inhibition with kinase inhibition in an all-oral treatment approach.
Dosing and Safety
The FDA-recommended regimen is belzutifan 120 mg once daily plus lenvatinib 20 mg once daily, continued until disease progression or unacceptable toxicity.
Belzutifan carries a boxed warning for embryo-fetal toxicity and warnings for anemia and hypoxia. Cardiac dysfunction is also identified as a warning and precaution for the combination. Lenvatinib has additional risks including hypertension, cardiac dysfunction, hepatotoxicity, renal impairment and proteinuria, gastrointestinal complications, QT prolongation, hemorrhagic events, thyroid dysfunction, impaired wound healing, and embryo-fetal toxicity.
Expanding Belzutifan’s Treatment Setting
The new approval differs from the FDA’s earlier approval of belzutifan for advanced RCC following treatment with both a PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. The September 2026 decision establishes belzutifan plus lenvatinib as an additional treatment option after PD-1 or PD-L1 inhibitor therapy.
The LITESPARK-011 findings demonstrate a statistically significant PFS benefit and higher ORR versus cabozantinib, while the final OS analysis did not show a statistically significant difference. The results provide the clinical basis for the FDA’s approval of the combination in advanced RCC with a clear cell component.
References
U.S. Food and Drug Administration. FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component. FDA, September 24, 2026.
A Study of Belzutifan (MK-6482) in Combination with Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011), ClinicalTrials.gov. NCT04586231
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.